Agree, there are some positives like the below:
Penetration continues to increase, with approximately 30% of the 5,000 diagnosed patients having initiated therapy. In market research, physicians surveyed stated that over the next 24 months they expect to expand prescribing to more than 70% of their eligible patients.
Once the FDA meeting is completed in September, and hopefully further indications announced the Board just needs to wrap a bow around the company.
Ann: Q2 2024 update, page-17
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.02 |
Change
0.080(0.62%) |
Mkt cap ! $1.664B | |||
| Open | High | Low | Value | Volume |
| $13.23 | $13.35 | $12.99 | $5.557M | 423.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1588 | $13.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.06 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |